Evidence map›Paper›PMID 16469267›Full record

ReviewCurrent neurology and neuroscience reports2006

Heart diseases and stroke.

Cathy A Sila

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Proteomics of the heart.Physiological reviews · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Cathy A SilaCerebrovascular Center, Section of Stroke and Neurologic Intensive Care, Cleveland Clinic, 9500 Euclid Avenue S-91, Cleveland, OH 44195, USA. silac@ccf.org
Cleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A heterogeneous group of heart diseases, varying by cardiac anatomy and physiology, are responsible for a variety of embolic materials that result in cerebral and systemic embolism. Atrial fibrillation accounts for nearly half of all cardioembolic stroke, particularly in the elderly, but in the young congenital septal abnormalities such as patent foramen ovale play a more important role. Therapeutic strategies include stabilization or treatment of the underlying heart disease and prevention of embolism. Oral anticoagulant therapy is indicated for many but decision making on balancing the benefits versus risks can be difficult. New endovascular therapies and devices have become available and await clinical trials that allow them to be compared with existing medical therapies.

Indexed as

Heart DiseasesStrokeAortaAtherosclerosisAtrial FibrillationCardiomyopathiesClinical Trials as TopicHeart AneurysmHeart Septal Defects, AtrialHumansVentricular Dysfunction, Left

Identifiers

PMID16469267
OpenAlexW1976289340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.